Molecular bacterial load assay: Method predicts effectiveness of tuberculosis therapy
Emerging drug-resistant strains are posing significant challenges to the global fight against tuberculosis (TB) and it is a critical task to detect treatment failure as early as possible.
New University%2c UC-Irvine5h
Psychedelics in clinical settings
Supporting the decriminalization and study of psychedelics is a bold but necessary step forward. Now is the time to prioritize science over stigma and embrace a progress-based approach to drug policy, ...
Daily Camera20h
Boulder Community Health now offering ketamine therapy, other therapies for treatment-resistant conditions
Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...
MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call
Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.
Targeted Oncology1d
FDA Grants Orphan Drug Designation to MB-105 for R/R T-Cell Lymphoma
MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...
Cure Today1d
FDA Accepts sNDA for Welireg in Advanced Pheochromocytoma and Paraganglioma
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...
New Atlas2d
Breast cancer cure rates almost doubled in combo therapy trial
A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...
Cure Today2d
FDA Approves Enhertu for HER2-Low and -Ultralow Breast Cancer
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...
Dual-targeted therapy plus chemo boosts response rate in BRAF-mutated metastatic colorectal cancer
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...
Medscape3d
Drug Combo for Common Neuroendocrine Tumor: A New Standard?
Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...
Science Daily5d
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...